BCAX: bicara.com Price/Earnings to Growth Multiple
Outsourcing production and testing allows Bicara Therapeutics Inc. (BCAX) to respond flexibly to market demand, as confirmed by the historical P/E-to-growth trend, where the latest parameter is 0.00. Business efficiency is based on a science-centric culture and expert options, while development acceleration is driven by AI modeling and automated drug synthesis.
Analytical breakdowns for Bicara Therapeutics Inc. (BCAX)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
BCAX - Company Net Income|Expected Net Income Bicara Therapeutics Inc.|BCAX - P/E Multiple|Forward P/E Multiple Bicara Corp|BCAX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Bicara Bio|BCAX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Bicara Therapeutics|BCAX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months bicara.com|BCAX - Earnings growth in current year|Expected net earnings per share growth next year Bicara Therapeutics Inc.
- total revenue and sales volume data:
General company analysis:BCAX, Bicara Therapeutics Inc
The PEG ratio compares a stock's market value with its net income growth, allowing for the determination of an asset's undervaluation relative to its expansion. For Bicara Therapeutics Inc. (BCAX), which implements AI algorithms and laboratory automation, the historical PEG level reflects the capitalization efficiency of these technological breakthroughs, helping investors distinguish the fundamental potential of this high-growth asset from temporary declines in operational productivity.
Competing companies
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Personalis Inc - Growth-Adjusted Payback Ratio|ERAS (Erasca Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Corp DCTH|PEG Multiple YMAB|Price/Earnings to Growth Ratio AURA (aurabiosciences.com)|PEG Multiple CADL (Candel Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Accuray Inc (ARAY)|SELLAS Life Sciences Group Inc. - PEG Multiple|Actuate Therapeutics Inc (ACTU) - Price/Earnings to Growth Multiple|CTOR: PEG Multiple|TuHURA Biosciences (HURA) - PEG Multiple|Price/Earnings to Growth Ratio Protara Therapeutics, Inc.|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|PEG Multiple tscan.com (TCRX)|Champions Oncology, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XBIT|CVM: Price/Earnings to Growth Multiple|OS Therapies Inc. - Company Value to Earnings Growth Ratio|RADX: PEG Multiple|Artiva Biotherapeutics - Growth-Adjusted Payback Ratio|ANL (Adlai Nortye Ltd) - PEG Multiple|Price to Earnings Adjusted for Growth Rate verupharma.com VERU|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|XLO (xiliotx.com) - Growth-Adjusted Payback Ratio|PEG Multiple RENB (Renovaro)|PEG Multiple Mural Oncology PLC MURA|KAPA - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio OKUR|GDTC: PEG Multiple|Price to Earnings Adjusted for Growth Rate Curis (CRIS)|Price/Earnings to Growth Multiple APLM|PEG Multiple Tharimmune Corporation|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc)|Company Value to Earnings Growth Ratio GNPX|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Sunshine Biopharma Inc. (SBFM)|Xenetic Bio - PEG Multiple|Salarius Pharma (SLRX) - Price/Earnings to Growth Multiple|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|AONC - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple BGNE|CKPT: Growth-Adjusted Payback Ratio|PEG Multiple ELEV|Growth-Adjusted Market Cap to Net Income icadmed.com|Price/Earnings to Growth Ratio Ikena Oncology IKNA|NTBL: Growth-Adjusted P/E Ratio|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA (NAYA Bio) - Price/Earnings to Growth Multiple|AAPGV - Growth-Adjusted Market Cap to Net Income
